secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-061101
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q3 net loss $10.4M; cash $43.4M; Phase 1a data expected Q1 2024
------------------------------------------------------------------------

- Net loss $10.4M vs $13.4M prior year; R&D expenses down to $6.1M from $8.6M.
- Cash and securities $43.4M (Sept 30, 2023), down from $53.4M (June 30, 2023); runway into 2025.
- Phase 1a data for SZN-043 and SZN-1326 expected Q1 2024; Phase 1b studies to initiate in 2024.
- Two new USPTO patents granted (Nos. 11/746,150 and 11/773,171) for SZN-1326 and SWAP technology.
- Boehringer Ingelheim partnership: potential $10M milestone in 2024 upon candidate nomination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023061101/0000950170-23-061101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017023061101/srzn-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer